Search

Your search keyword '"Anwer, Faiz"' showing total 1,549 results
Start Over Author "Anwer, Faiz"
1,549 results on '"Anwer, Faiz"'

3. Impact of Extraosseous Extramedullary Disease on Outcomes of Patients with Relapsed-Refractory Multiple Myeloma receiving Standard-of-Care Chimeric Antigen Receptor T-Cell Therapy

Author

Dima, Danai, Abdallah, Al-Ola, Davis, James A., Awada, Hussein, Goel, Utkarsh, Rashid, Aliya, DeJarnette, Shaun, Anwer, Faiz, Shune, Leyla, Raza, Shahzad, Mahmoudjafari, Zahra, Williams, Louis, Faiman, Beth, McGuirk, Joseph P., Sauter, Craig S., Ahmed, Nausheen, Khouri, Jack, and Hashmi, Hamza

Published
2024
Full Text
View/download PDF

17. Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience

Author

Khouri, Jack, Dima, Danai, Li, Hong, Hansen, Doris, Sidana, Surbhi, Shune, Leyla, Anwer, Faiz, Sborov, Douglas, Wagner, Charlotte, Kocoglu, Mehmet H., Atrash, Shebli, Voorhees, Peter, Peres, Lauren, Hovanky, Vanna, Simmons, Gary, Williams, Louis, Raza, Shahzad, Afrough, Aimaz, Anderson, Larry D., Jr, Ferreri, Christopher, Hashmi, Hamza, Davis, James, McGuirk, Joseph, Goldsmith, Scott, Borogovac, Azra, Lin, Yi, Midha, Shonali, Nadeem, Omar, Locke, Frederick L., Baz, Rachid, Hamilton, Betty, Alsina, Melissa, Sauter, Craig, Patel, Krina, and Kaur, Gurbakhash

Published
2024
Full Text
View/download PDF

19. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma

Author

Lin, Cindy Hsin-Ti, primary, Tariq, Muhammad Junaid, additional, Ullah, Fauzia, additional, Sannareddy, Aishwarya, additional, Khalid, Farhan, additional, Abbas, Hasan, additional, Bader, Abbas, additional, Samaras, Christy, additional, Valent, Jason, additional, Khouri, Jack, additional, Anwer, Faiz, additional, Raza, Shahzad, additional, and Dima, Danai, additional

Published
2024
Full Text
View/download PDF

20. Efficacy of low-dose direct oral anticoagulants (DOACs) for venous thromboembolism prophylaxis in newly diagnosed multiple myeloma.

Author

Basali, Diana, primary, Zureigat, Hadil, additional, Nurse, Daniel Paul, additional, Elmaleh, Hassan, additional, Batah, Heya, additional, Adcock, Bridget, additional, Wei, Wei, additional, Dima, Danai, additional, Valent, Jason Neil, additional, Anwer, Faiz, additional, Samaras, Christy Joy, additional, Khouri, Jack, additional, Williams, Louis, additional, Raza, Shahzad, additional, van Heeckeren, Willem Jan, additional, and Mazzoni, Sandra Ann, additional

Published
2024
Full Text
View/download PDF

21. Characterizing clinical trials for CAR T targeting solid tumors from 2018 to 2023: A systematic review.

Author

Wesson, William, primary, Ayoobkhan, Fathima Shehnaz, additional, Mahmoudjafari, Zahra, additional, Mushtaq, Muhammad Umair, additional, Abdallah, Al-Ola A., additional, Sun, Weijing, additional, Anwer, Faiz, additional, Doolittle, Gary C., additional, McGuirk, Joseph, additional, Al-Rajabi, Raed Moh'd Taiseer, additional, Baranda, Joaquina Celebre, additional, and Ahmed, Nausheen, additional

Published
2024
Full Text
View/download PDF

22. Trends in hospice utilization and place of death preferences in multiple myeloma-related deaths from 2003 to 2020: Analysis of CDC Wonder database.

Author

Faisal, Muhammad Salman, primary, Sukaina, Mahnoor, additional, Mishra, Rahul, additional, Khosla, Atulya Aman, additional, Batra, Nitya, additional, Kumar, Madhan Srinivasan, additional, Soror, Noha, additional, Ahmad, Zain Ishtiaq, additional, Jatwani, Karan, additional, and Anwer, Faiz, additional

Published
2024
Full Text
View/download PDF

28. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.

Author

Dima, Danai, Hughes, Michael, Orland, Mark, Ullah, Fauzia, Goel, Utkarsh, Anwer, Faiz, Raza, Shahzad, Mazzoni, Sandra, Bhutani, Divaya, Williams, Louis, Lentzsch, Suzanne, Samaras, Christy, Valent, Jason, Chakraborty, Rajshekhar, and Khouri, Jack

Subjects
OVERALL survival, FAILURE (Psychology), SALVAGE therapy, TREATMENT failure, CARDIAC patients
Abstract

Background: Daratumumab's incorporation in the upfront treatment of light chain (AL) amyloidosis has led to daratumumab (dara) refractoriness early in disease course. Patients who experience relapse or have suboptimal response to dara-based-therapy, have limited options. Objective: This study aimed to evaluate the outcomes of venetoclax-based therapy in t(11;14) positive AL patients who previously failed dara. Methods: Thirty-one patients with AL were included in this bi-institutional retrospective analysis. Results: Dara failure was due to inadequate response in 20 (65%) patients, haematologic relapse in 7 (22%), and both haematologic plus organ relapse in 4 (13%). Overall haematologic response rate to venetoclax-based therapy was 97%, with ≥ VGPR being 91%. Of the 19 evaluable patients with cardiac involvement, 14 (74%) achieved organ response. Of the 13 evaluable patients with renal involvement, 6 (46%) achieved organ response. With a median follow-up of 22 months, median time-to-next-treatment (TTNT) and overall survival (OS) were not reached. The 12- and 24-month TTNT rates were 74% and 56%, respectively. At data-cut-off, four patients had died, all from AL-related organ complications. The 12- and 24-month OS rates were 89% and 85%, respectively. Grade ≥3 adverse events occurred in 26% of patients, with 6% due to infections. Conclusion: These findings are encouraging for the use of venetoclax as salvage therapy post-dara failure. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Yield of repeat blood cultures in acute myeloid leukemia patients with febrile neutropenia and bacteremia following allogeneic hematopoietic stem cell transplant.

Author

Sheu, Michael, Molina Garcia, Sofia, Shrivastava, Gautam, Patel, Meera, Mushtaq, Ali, Crilley, Thomas, Anwer, Faiz, and Majeed, Aneela

Subjects
HEMATOPOIETIC stem cell transplantation, HEMATOPOIETIC stem cells, ACUTE myeloid leukemia, STEM cell transplantation, FEBRILE neutropenia
Abstract

Introduction: This study explored the efficacy of repeat blood cultures in bacteremic acute myeloid leukemia (AML) patients following allogeneic hematopoietic stem cell transplantation (HSCT). Methods: This was a retrospective study of AML patients who experienced febrile neutropenia (FN) and bacteremia following HSCT at the Taussig Cancer Center from January 1, 2019, to December 31, 2022. The primary endpoint was the rate of positive repeat blood cultures following initial positive blood culture. Results: Fifty patients were included in the study. There were 50 occurrences of FN with positive initial blood cultures that were diagnosed following HSCT. Fifty initial sets of blood cultures and 96 sets of repeat blood cultures were drawn between the 50 occurrences of FN. Twelve of 96 (12.5%) repeat blood culture sets were positive for a pathogen, which occurred over nine of 50 (18.0%) episodes of FN. Three of 96 (3.2%) repeat blood culture sets grew a pathogen that differed from the pathogen that grew in the preceding positive blood culture. Conclusion: Among bacteremic AML patients in the post‐HSCT period, the yield of repeat blood cultures for detecting previously detected and new pathogens was low. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy.

Author

Dima, Danai, Goel, Utkarsh, Sannareddy, Aishwarya, Ibeh, Nnaemeka, Ullah, Fauzia, Afrough, Aimaz, Mazzoni, Sandra, Mehdi, Ali, Rudoni, Joslyn, Raza, Shahzad, De Simone, Nicole, Williams, Louis, Khan, Adeel, Rashid, Aliya, Rice, Mikhaila, Ricci, Kristin, Samaras, Christy, Valent, Jason, Anderson, Larry D., and Anwer, Faiz

Subjects
PLASMA exchange (Therapeutics), TREATMENT effectiveness, MULTIPLE myeloma, IMMUNOGLOBULIN light chains, KIDNEY diseases
Abstract

Current treatment guidelines of myeloma cast nephropathy (MCN) recommend the institution of plasma cell‐directed therapy and consideration of therapeutic plasma exchange (TPE), with the goal of rapid reduction of the serum free light chain (sFLC). However, the role of TPE continues to remain a subject of debate. The goal of this retrospective bi‐institutional study was to evaluate the clinical outcomes of TPE in combination with systemic therapy. Eighty patients were included in this analysis, of whom 72.5% had ≥50% drop in their initial involved sFLC. At 3 months from TPE initiation, the overall hematologic response rate (ORR) was 67.5% with a very good partial response or better (≥VGPR) rate of 40%. At 6 months, ORR was 57.5%, with ≥VGPR rate of 49%. The renal response rate at 3 and 6 months was 47.5% and 43.75%, respectively; the overall renal response rate was 48.75%. On multivariable analysis, every one unit increase in baseline creatinine (odds ratio [OR] 0.76, p = 0.006), and achievement of ≥VGPR (OR 21.7 p < 0.0001) were significantly associated with renal response. Also, a ≥50% drop in sFLC was favorably associated with renal response (OR 3.39, p = 0.09). With a median follow‐up of 36.4 months, the median overall survival (OS) was 11 months. On multivariable analysis, achievement of renal response (hazard ratio [HR] 0.3, p < 0.0001) and newly diagnosed disease (NDMM; HR 0.43, p = 0.0055) were associated with improved OS. Among NDMM patients, those treated with daratumumab‐based regimens had a trend for better OS (p = 0.15), compared to other regimens, but the difference was not significant. At the end of follow‐up, an estimated 40.4% of patients who were on dialysis were able to become dialysis independent. In conclusion, our study highlights the poor survival of patients with MCN. Achievement of early renal response is crucial for prolonged OS, with daratumumab‐based therapies showing promise. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Author

Gagelmann, Nico, primary, Dima, Danai, additional, Merz, Maximilian, additional, Hashmi, Hamza, additional, Ahmed, Nausheen, additional, Tovar, Natalia, additional, Oliver-Caldés, Aina, additional, Stölzel, Friedrich, additional, Rathje, Kristin, additional, Fischer, Luise, additional, Born, Patrick, additional, Schäfer, Lisa, additional, Albici, Anca-Maria, additional, Schub, Natalie, additional, Kfir-Erenfeld, Shlomit, additional, Assayag, Miri, additional, Asherie, Nathalie, additional, Wulf, Gerald Georg, additional, Kharboutli, Soraya, additional, Müller, Fabian, additional, Shune, Leyla, additional, Davis, James A., additional, Anwer, Faiz, additional, Vucinic, Vladan, additional, Platzbecker, Uwe, additional, Ayuk, Francis, additional, Kröger, Nicolaus, additional, Khouri, Jack, additional, Gurnari, Carmelo, additional, McGuirk, Joseph, additional, Stepensky, Polina, additional, Abdallah, Al-Ola, additional, and Fernández de Larrea, Carlos, additional

Published
2024
Full Text
View/download PDF

38. The TACTUM23 Study: Access to Cellular Therapies in Multiple Myeloma: Perspectives of Treating Versus Referring Physicians in 2023

Author

Atallah, Rawan, primary, Saif, Md Saiful Islam, additional, Danai, Dima, additional, Shrestha, Anuj, additional, Anwer, Faiz, additional, Mushtaq, Muhammad Umair, additional, Lutfi, Forat, additional, Shune, Leyla, additional, Hashmi, Hamza, additional, Ganguly, Siddhartha MD, additional, McGuirk, Joseph P, additional, Atrash, Shebli, additional, Abdallah, Al-Ola, additional, Banerjee, Rahul, additional, Ahmed, Nausheen, additional, and Logan, Emerson, additional

Published
2024
Full Text
View/download PDF

39. Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Not Meeting the Karmma-1 Trial Eligibility Criteria: A Real-World Multicenter Study from the US Myeloma Innovations Research Collaborative (USMIRC)

Author

Dima, Danai, primary, Rashid, Aliya, additional, Davis, James, additional, Awada, Hussein, additional, Abdallah, Al-Ola, additional, DeJarnette, Shaun, additional, Shune, Leyla, additional, Khouri, Jack, additional, Hashmi, Hamza, additional, McGuirk, Joseph P, additional, Anwer, Faiz, additional, and Ahmed, Nausheen, additional

Published
2024
Full Text
View/download PDF

40. A Multicenter Experience: Duration of Mandatory CRS and Icans Monitoring for Myeloma and Lymphoma CAR-T Recipients

Author

Wesson, William, primary, Dima, Danai, additional, Davis, James, additional, Rashid, Aliya, additional, Furqan, Fateeha, additional, Saif, Md Saiful Islam, additional, Logan, Emerson, additional, McGann, Mary, additional, Tabak, Carine, additional, Hazlett, Liz, additional, Lutfi, Forat, additional, Mushtaq, Muhammad Umair, additional, Hoffmann, Marc, additional, Abdallah, Al-Ola, additional, Anwer, Faiz, additional, Hamadani, Mehdi, additional, McGuirk, Joseph P, additional, Hashmi, Hamza, additional, and Ahmed, Nausheen, additional

Published
2024
Full Text
View/download PDF

42. Neighborhood Socioeconomic Disadvantage and Distance from Treatment Center Do Not Impact Survival Outcomes of Patients with Non-Hodgkin's Lymphoma (NHL) and Multiple Myeloma (MM) Treated with CAR T-Cell Therapies.

Author

Mian, Agrima, primary, Dima, Danai, additional, Hamilton, Betty K., additional, Winter, Allison, additional, Khouri, Jack, additional, Williams, Louis, additional, Raza, Shahzad, additional, Jagadeesh, Deepa, additional, Gerds, Aaron T., additional, Dean, Robert M., additional, Sobecks, Ronald M., additional, Kalaycio, Matt E., additional, Brunstein, Claudio G., additional, Sauter, Craig S, additional, Anwer, Faiz, additional, Hill, Brian T., additional, and Caimi, Paolo, additional

Published
2024
Full Text
View/download PDF

43. Outcomes of BCMA-Directed Chimeric Antigen Receptor T-Cell (CART) Therapy and Teclistamab in Patients with Relapse-Refractory Multiple Myeloma with Extramedullary Disease: A Real-World Experience of the US Myeloma Innovations Research Collaborative (USMIRC)

Author

Dima, Danai, primary, Davis, James, additional, Ahmed, Nausheen, additional, Sannareddy, Aishwarya, additional, Shaikh, Hira, additional, Shune, Leyla, additional, Kaur, Gurbakhash, additional, Khouri, Jack, additional, Afrough, Aimaz, additional, Strouse, Christopher Sun, additional, Lochner, Jonathan, additional, Mahmoudjafari, Zahra, additional, Raza, Shahzad, additional, Valent, Jason, additional, Anderson, Larry D., additional, Anwer, Faiz, additional, Hashmi, Hamza, additional, and Abdallah, Al-Ola, additional

Published
2024
Full Text
View/download PDF

46. Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa‐1 trial eligibility criteria: A real‐world multicentre study

Author

Dima, Danai, primary, Rashid, Aliya, additional, Davis, James A., additional, Shune, Leyla, additional, Abdallah, Al‐Ola, additional, Li, Hong, additional, DeJarnette, Shaun, additional, Khouri, Jack, additional, Williams, Louis, additional, Hashmi, Hamza, additional, Raza, Shahzad, additional, McGuirk, Joseph, additional, Anwer, Faiz, additional, and Ahmed, Nausheen, additional

Published
2024
Full Text
View/download PDF

47. Incidence and Risk of Secondary Malignancy in Patients with Waldenström Macroglobulinemia: A Population-Based Analysis

Author

Rehman, Mohammad Ebad Ur, primary, Hameed, Maha, additional, Shah, Zunairah, additional, Ashruf, Omer S, additional, Ali, Rabia, additional, Faraz, Fatima, additional, Basit, Jawad, additional, Khan, Israr, additional, Fazal, Faizan, additional, Iftikhar, Ahmad, additional, Nashwan, Abdulqadir J, additional, Faisal, Muhammad Salman, additional, and Anwer, Faiz, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results